Sign in
CompletedNo phase

Remote Treatment of Alcohol Withdrawal

Key facts

Who runs it
Centre for Addiction and Mental Health
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
30 people enrolled
Started
24 Sept 2021
Ended
21 Nov 2023
Type of study
Interventional
Treatments tested
  • Diazepam
Record updated
14 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Adults 18 years and older
  • Are actively using alcohol
  • Previously met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) B criteria for alcohol withdrawal
  • Aim to achieve at least 30 days of abstinence as a treatment goal following initiation of remote alcohol withdrawal management
  • Are able to provide informed consent in English
  • Reside or are able to stay at an address within 2-hours travelling distance from the Centre for Addiction and Mental Health for the entire duration of the remote withdrawal procedure
  • Are enrolled in the Ontario Health Insurance Plan (OHIP)

Who cannot take part

  • History of complicated withdrawal including withdrawal seizures, hallucinosis, or delirium
  • Positive UDS for sedatives or opioids, currently prescribed sedatives or opioids, or diagnosis of sedative-hypnotic or opioid use disorder within the past year (based on assessment). Individuals prescribed low doses of benzodiazepines (e.g. lorazepam 1mg PO daily) or with a positive urine benzodiazepine screen that is not thought to be due to benzodiazepine misuse may be permitted to proceed with the study at the discretion of the study physician
  • Severe medical or psychiatric comorbidity that would prevent safe participation in the study
  • Contraindications to the safe use of diazepam including: known hypersensitivity to diazepam severe respiratory insufficiency, severe hepatic insufficiency, sleep apnea syndrome, acute narrow-angle glaucoma, and myasthenia gravis. Individuals with sleep apnea may be permitted to proceed with the study at the discretion of the study physician
  • Active withdrawal symptoms (CIWA-Ar > 12) at the time of the eligibility assessment
  • Active suicidal ideation at the time of eligibility assessment
  • Positive urine pregnancy test, actively breastfeeding, or planning to become pregnant or breastfeed during the study period
  • Lack of stable housing
  • Enrollment in another study that conflicts with the procedures or scientific integrity of this study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will evaluate the feasibility of delivering symptom-triggered alcohol withdrawal management by telemedicine and determine whether this intervention is satisfactory to patients.

The group in the trial

  • Symptom-triggered diazepam treatmentTreatment being tested

    Participants will be treated for a period of 3 days using a symptom-triggered withdrawal management protocol delivered over telemedicine. Participants who score 10 or above on the modified CIWA-Ar will be advised to take a specific dose of diazepam (either 10 or 20mg, at the clinician's discretion). Participants will be reassessed regularly over the 3-day period.

    Treatment: Diazepam

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Remote Treatment of Alcohol Withdrawal: A Pilot Study
Record updated
14 May 2026